Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRADI trial of bevacizumab versus placebo for corticosteroid-dependent or corticosteroid-resistant brain radionecrosis after radiotherapy for brain metastases
2024-510893-25-00Phase 3Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in brain radionecrosis comparing Bevacizumab with Placebo (2 arms). Primary endpoints: Corticosteroid dose change and Neurologic function by NANO. Planned start Jun 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
brain radionecrosis
Beyond the preview
Go deeper on 2024-510893-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510893-25-00.